Debates

Most Crohn’s disease patients who undergo an intestinal resection will have postoperative recurrence. The most effective way to prevent recurrence is to initiate an anti-TNF within four weeks of surgery. It has been my practice that patients at high risk for postoperative Crohn’s disease recurrence initiate anti-TNF shortly after they are discharged from the hospital. […]

Debates

A surgical resection for a patient with Crohn’s disease is a major milestone in the natural history of their condition. It is without a doubt that patients who require surgery will make avoiding further surgery a priority and accordingly many patients will consider any possible preventive measure. I explain to patients that surgery is usually […]

Quick Hits

Vedolizumab (Entyvio, Takeda Pharmaceuticals America, Deerfield, IL) is a humanized monoclonal antibody to α-4 β-7 integrin, which is expressed on lymphocytes and is the ligand to mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1), preferentially expressed on endothelial cells in the gut vasculature. Vedolizumab selectively interferes with lymphocyte homing in the gut, thus affording the potential […]